The global antibody drug conjugates market size was valued at USD 7.82 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 11.2% from 2023 to 2030. The market is primarily driven by rising incidence of cancer globally. According to Cancer Research UK estimates the number of new cancer cases worldwide is expected to reach 27.5 million by 2040. Factors such as smoking, unhealthy diet, obesity, and alcohol are the major cause of rising cancer cases worldwide. The COVID-19 pandemic had a negative impact on the product sale due to loss of health insurance coverage, decrease in hospital visits, and lower diagnosis rates. Unavailability of participants for clinical trial studies led to delay in potential approval of antibody drug conjugates (ADC)s such as Adcetris for other indications.
Increasing investment in this field by key players such as Piramal Pharma Solution, Pfizer Inc., Seagen Inc., and F. Hoffman La-Roche Ltd for the development of new ADCs for the treatment of cancer is anticipated to drive market growth. For instance, in February 2022, CDMO Piramal Pharma Solutions (PPS) invested about USD 74.6 million for the development of two new antibody-drug conjugates (ADC) production facilities at its existing sites of Grangemouth, Scotland to fulfil the growing demand for commercial ADCs in UK. This investment strengthens PPS’ position in the market significantly increasing ADC manufacturing capacity.
Most of the companies are conducting clinical trials to bring new products to the market and to gain label expansion for their already approved products. For instance, in January 2022, Seagen initiated phase 1 clinical trials of two novel antibody-drug conjugates such as SGN-B7H4V & SGN-PDL1V in patients with advanced solid tumors. In addition, the company in collaboration with Astellas completed enrollment of patients for cohort K EV-103 trial for the treatment of First-Line Metastatic Urothelial Cancer (mUC). Successful completion of the clinical trial study and subsequent approval of products is anticipated to drive market growth.
Breast cancer accounted for the largest revenue share of 50.61% in 2022 owing to relatively high prevalence of the disease worldwide. According to WHO, worldwide there were around 2.26 million new breast cancer cases diagnosed in 2020 and estimated deaths due to cancer were 685,000. There are three antibody-drug conjugate products available for the treatment of breast cancer as; Trodelvy from Gilead Sciences, Inc.; Enhertu from AstraZeneca; and Kadcyla from Hoffmann-La Roche Ltd. Providing these drugs under patient assistance program is expected to drive market growth. Kadcyla offers financial assistance to eligible patients who are publicly & commercially insured.
Blood cancer segment is expected to grow with the CAGR 10.7% during the forecast period. Blood cancer is the fifth most common cancer and is the second leading cause of cancer deaths globally. According to the National Foundation of Cancer Research, in the U.S., a total of 186,400 new cases of leukaemia, lymphoma, and myeloma were diagnosed in 2021. Furthermore, the approval for multiple products during the forecast period is expected to drive market growth. For instance, a new product, Polivy, was launched in the market in October 2019 for the treatment of diffuse large B-cell lymphoma (DLBCL).
The cleavable linker segment accounted for largest revenue share of 65.20% in 2022. The ability of cleavable linkers to remain stable in the bloodstream for longer duration & release of cytotoxins from ADCs makes them the most popular used technology for an effective outcome of ADCs in cancer treatment. For instance, in 2020, Seagen’s & Takeda’s Adcetris was approved by NMPA for use in the treatment of relapsed Hodgkin's lymphoma and relapsed systemic anaplastic large cell lymphoma sALCL in China. Such factors are expected to drive the cleavable linker market segment during the forecast period.
Non-cleavable linker was the second largest revenue-generating segment in 2022 owing to the increase in usage of Kadcyla, which contains a non-cleavable linker. Non-cleavable linker is used for the production of ADCs that are reliant on the ADC’s lysosomal degradation and prevents the non-specific release of the drug, thus reducing the overall cytotoxicity of the ADC to surrounding healthy cells. This is expected to drive the segment during the forecast period. Currently, only FDA approved ADCs such as Kadcyla and Blenrep use non-cleavable linkers for binding the antibody and cytotoxic molecule
Linker is the key component of ADCs and it connects the antibody & cytotoxic payload. It imparts the characteristics to ADCs such as high stability in circulation and specific release of payload in the target tissue. There are number of linkers available in the market which includes VC, Sulfo-SPDB, VA, Hydrazone, SMCC, SPP, MCC, maleimide tetrapeptide, CL2A, and MC are used to deliver payloads to their target sites.
Payloads are cytotoxic agents that are used to kill target cancerous cells. Currently, there are many payloads available in the market including microtubuline inhibitors (Vinorelbine, Paclitaxel, Epothilone B, Tubulysins (IM-2, B), DNA cleavers (Bleomycin A2), Akt inhibitors (GDC - 0068), DNA intercalators (Doxorubicin hydrochloride, Epirubicin hydrochloride, Duocarmycins, PBD dimers), MMAF & MMAE. Currently, Blenrep (belantamab mafodotin-blmf) developed by GlaxoSmithKline plc. utilizes MMAF, protease linker, and anti-CD38 monoclonal antibody to kill target cell in adult patients with relapsed multiple myeloma.
North America dominated the market in terms of revenue share of 53.29% in 2022. The well-established research facilities for the development of novel ADCs, rising per capita healthcare expenditure, and increase prevalence of cancer are the major factors for the dominance of the region. As per the American Cancer Society estimates, the incidence of cancer reached 1.9 million in 2022 and around 609,360 deaths in the U.S. The approval of new ADCs in the region is expected to drive market growth. For instance, in September 2021, the U.S. FDA approved Tidvak for the treatment of adult patients with metastatic or recurrent cervical cancer.
Asia Pacific antibody-drug conjugates market is expected to witness a CAGR of 12.9% over the forecast period. The growth of region is attributable to the approval of new ADCs in the region. For instance, in May 2021, Japan’s MHLW granted priority review to Astellas’s enfortumab vedotin for the treatment of metastatic or locally advanced urothelial cancer.
The leading players are focusing on growth strategies, such as innovations in the existing product, approval of new products, licensing agreements, and mergers & acquisitions to gain market share. For instance, in March 2023, AstraZeneca completed a licensing agreement with KYM Biosciences for CMG-901. It is a potential ADC being evaluated in a phase 1 clinical trial currently and targets Claudin 18.2, a promising target for gastric cancer. Some of the prominent players in the global antibody drug conjugates market include:
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Daiichi Sankyo Company Limited
Astellas Pharma, Inc.
Market size value in 2023
USD 10.61 billion
Revenue forecast in 2030
USD 22.35 billion
CAGR of 11.2% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion, and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Application, technology, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Spain; Italy; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd; Pfizer, Inc.; AstraZeneca; Gilead Sciences, Inc.; Astellas Pharma; Seagen, Inc.; Daiichi Sankyo Company Limited; GlaxoSmithKline Plc; ADC Therapeutics SA
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global antibody drug conjugates market report on the basis of application, technology, and region:
Application Outlook (Revenue, USD Million, 2018 - 2030)
Urothelial Cancer & Bladder Cancer
Technology Outlook (Revenue, USD Million, 2018 - 2030)
Linker Technology Type
Regional Outlook (Revenue, USD Million, 2018 - 2030)
b. The global antibody-drug conjugates market is expected to grow at a compound annual growth rate of 11.2% from 2023 to 2030 to reach USD 22.35 billion by 2030.
b. Based on application, the breast cancer segment dominated the antibody-drug conjugate market with a share of 50.61% in 2022. A higher number of approved products and label expansion of currently approved products for early-stage breast cancer are some of the key factors driving the growth of this segment.
b. Some key players operating in the antibody-drug conjugates market include Seagen, Inc.; Takeda Pharmaceutical Company Limited; AstraZeneca Plc, F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; ADC Therapeutics; Astellas Pharma; Gilead Sciences, Inc.; GlaxoSmithKline Plc; and Daiichi Sankyo Company Limited.
b. Key factors that are driving the antibody-drug conjugates market growth include the increasing prevalence of cancer and the impending approval of new products such as Tisotumab Vedotin, Camidanlumab Tesirine, and trastuzumab Duocarmazine amongst others.
b. The global antibody-drug conjugates market size was estimated at USD 7.82 billion in 2022 and is expected to reach USD 10.61 billion in 2023.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."